Want to see ELTX full AI Analyst Report?
ELTX Stock Chart & Stats
$3.00
$0.02(0.67%)
At close: 4:00 PM EDT
$3.00
$0.02(0.67%)
Day’s Range― - ―
52-Week Range$2.66 - $16.00
Previous CloseN/A
Volume163.39K
Average Volume (3M)3.31M
Market Cap
$68.29M
Enterprise Value$194.08
Total Cash (Recent Filing)$14.95M
Total Debt (Recent Filing)$14.34M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 07, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding23,466,394
10 Day Avg. Volume474,004
30 Day Avg. Volume3,311,596
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.67Price Target Upside588.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological Activity & Checkpoint SynergyDurable immunologic activity and observed complete responses when followed by anti–PD‑1 suggest ELI‑002 7P can prime tumors for checkpoint sensitivity. This biological signal supports a differentiated combination strategy and could materially shorten development timelines if replicated prospectively.
Refined Registrational StrategyManagement’s pivot to an R0 resected cohort with a focused DFS endpoint shows strategic learning from Phase 2. Concentrating on a biologically responsive subgroup and adapting dosing increases statistical power and regulatory clarity, improving odds of a successful registrational path over the medium term.
Incremental Financing Extends RunwayA $15M registered direct raise materially boosts near‑term liquidity to execute planned Phase 1/Phase 3 activities. While dilutive, the financing reduces immediate funding uncertainty and enables clinical milestones that can de‑risk the platform and attract partners, supporting execution over the coming quarters.
Bears Say
No Revenue And Heavy Cash BurnAs a development‑stage biotech without product revenue, persistent ~-$38M annual cash burn forces reliance on external financing. That ongoing funding dependency creates dilution risk and limits strategic flexibility, making sustained R&D progress contingent on successful raises or partnerships.
Missed Phase 2 Primary EndpointFailure to meet the Phase 2 primary endpoint increases clinical and regulatory risk, likely requiring refined trials and added data to convince regulators or partners. Post‑hoc subgroup signals help but do not replace prospective success, potentially lengthening timelines and raising development costs.
Weak Balance Sheet And Elevated LeverageNegative equity and a small asset base limit capital resilience. Elevated leverage and a weakened capital structure constrain options for non-dilutive financing, increase refinancing risk, and could raise the cost of capital or hamper ability to fund expanded registrational programs without partnering.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics, Inc’s price range in the past 12 months?
Elicio Therapeutics, Inc lowest stock price was $2.66 and its highest was $16.00 in the past 12 months.
What is Elicio Therapeutics, Inc’s market cap?
Elicio Therapeutics, Inc’s market cap is $68.29M.
When is Elicio Therapeutics, Inc’s upcoming earnings report date?
Elicio Therapeutics, Inc’s upcoming earnings report date is Aug 07, 2026 which is in 6 days.
How were Elicio Therapeutics, Inc’s earnings last quarter?
Elicio Therapeutics, Inc released its earnings results on May 11, 2026. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.465 by -$0.185.
Is Elicio Therapeutics, Inc overvalued?
According to Wall Street analysts Elicio Therapeutics, Inc’s price is currently Undervalued.
Does Elicio Therapeutics, Inc pay dividends?
Elicio Therapeutics, Inc does not currently pay dividends.
What is Elicio Therapeutics, Inc’s EPS estimate?
Elicio Therapeutics, Inc’s EPS estimate is -0.54.
How many shares outstanding does Elicio Therapeutics, Inc have?
Elicio Therapeutics, Inc has 23,466,394 shares outstanding.
What happened to Elicio Therapeutics, Inc’s price movement after its last earnings report?
Elicio Therapeutics, Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.465. Following the earnings report the stock price went down -9.13%.
Which hedge fund is a major shareholder of Elicio Therapeutics, Inc?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (588.89% Upside)
$20.67 (588.89% Upside)
Blogger Sentiment
Bearish
ELTX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.38%
Trailing 12-Months
Company Description
Elicio Therapeutics, Inc
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$20.67
▲(588.89% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
0.95% Insiders
2.68% Mutual Funds
0.17% Other Institutional Investors
91.28% Public Companies and
Individual Investors